An innovative medical biotechnology companyAbout us
Anocca, a privately held Swedish biotechnology company, was founded in 2014 with the ambition to create a new generation of immunotherapies. The aim was to construct a technology platform that addresses the fundamental technological limitations to deploying immunotherapies that direct, or redirect, the adaptive immune system.
This technology platform is now operational; comprising industrialised cell biology and genetics platforms capable of systematically and reproducibly extracting precise information about the immune system, which is essentially unique to each person.
Based in modern facilities near Stockholm, Sweden, Anocca has built up a talented team of around 30 scientists from 18 different nations. Alongside the immunotechnology platform, the Anocca team has established an advanced manufacturing infrastructure to produce cellular therapeutics for clinical use, which is approved for GMP production by the Swedish Medical Products Agency.
In the coming period, Anocca will leverage its unique technology platform and manufacturing capabilities to deliver our first clinical trials for TCR-modified T-cell therapies in highly segmented patient populations within oncology. Complementary clinical programs with a fully individualised strategy for targeting the unique aspects of an individual’s cancer cells will also be deployed in the near term. Anocca’s technologies will enable the delivery of these transformative cellular therapies for a wide range of cancer types, in almost any individual.